Journal: European journal of medicinal chemistry
Article Title: (+)-and (-)-Phenazocine enantiomers: Evaluation of their dual opioid agonist/? 1 antagonist properties and antinociceptive effects.
PMID/MRN: 27721146
Publication Date: 2017-Jan-05
Abstract:
cis-N-Substituted N-normetazocine enantiomers possess peculiar pharmacological profiles. Indeed, dextro enantiomers bind with high affinity ? 1 receptor while opposite enantiomers bind opioid receptors. In spite of their stereochemistry, cis-N-2-phenylethyl N-normetazocine (phenazocine) enantiomers showed mixed opioid/? 1 receptor profiles and a significant inÊvivo analgesia. To the best of our knowledge, there is no information available regarding the evaluation of ? 1 pharmacological profile in the antinociceptive effects of (+)- and (-)-phenazocine. Therefore, the present study was designed to ascertain this component by inÊvitro and inÊvivo studies. In particular, we tested the ? 1 affinity of both enantiomers by a predictive binding assay in absence or presence of phenytoin (DPH). Our results showed that DPH (1ÊmM) did not increase the ? 1 receptor affinity of (+)-and (-)-phenazocine (K i Ê=Ê3.8ʱÊ0.4ÊnM, K i Ê=Ê85ʱÊ2.0ÊnM, respectively) suggesting a ? 1 antagonist profile of both enantiomers. This ? 1 antagonistic component of two phenazocine enantiomers was corroborated by inÊvivo studies in which the selective ? 1 receptor agonist PRE-084, was able to unmask their ? 1 antagonistic component associated with the opioid activity. The ? 1 antagonistic component of (+)- and (-)-phenazocine may justify their analgesic activity and it suggests that they may constitute useful lead compounds to develop new ligands with this dual activity.
Copyright å© 2016 Elsevier Masson SAS. All rights reserved.